These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31043468)

  • 21. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Pitart C; Marco F; Keating TA; Nichols WW; Vila J
    Antimicrob Agents Chemother; 2015; 59(6):3059-65. PubMed ID: 25753646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro susceptibility of urinary pathogens to quinolones compared to other antimicrobial agents.
    Osman LM; Sabbour MS; el-Baz F
    Chemioterapia; 1987 Jun; 6(2 Suppl):147-8. PubMed ID: 3151335
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
    Kassim A; Omuse G; Premji Z; Revathi G
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.
    Chastain DB; Ngando I; Bland CM; Franco-Paredes C; Hawkins WA
    Ann Clin Microbiol Antimicrob; 2017 May; 16(1):43. PubMed ID: 28558707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.
    Nichols WW; Stone GG; Newell P; Broadhurst H; Wardman A; MacPherson M; Yates K; Riccobene T; Critchley IA; Das S
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30061279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.
    Hombach M; Bloemberg GV; Böttger EC
    J Antimicrob Chemother; 2012 Mar; 67(3):622-32. PubMed ID: 22167240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revision of fluoroquinolone breakpoints used for interpretation of antimicrobial susceptibility testing of canine bacterial isolates.
    Papich MG; Gunnett LA; Lubbers BV
    Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37673214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa.
    Hamada Y; Sutherland CA; Nicolau DP
    J Clin Microbiol; 2015 May; 53(5):1712-4. PubMed ID: 25694527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The New, New Daptomycin Breakpoint for
    Humphries RM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31092593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).
    Pogue JM; Jones RN; Bradley JS; Andes DR; Bhavnani SM; Drusano GL; Dudley MN; Flamm RK; Rodvold KA; Ambrose PG
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.
    Hackel MA; Badal RE; Bouchillon SK; Biedenbach DJ; Hoban DJ
    Surg Infect (Larchmt); 2015 Jun; 16(3):298-304. PubMed ID: 25894976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transferable fluoroquinolone resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolated from hemocultures.
    Kulková N; Babálová M; Brnová J; Krcméry V
    Cent Eur J Public Health; 2014 Mar; 22(1):60-3. PubMed ID: 24844110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.